4Antithrombotic Trialist' Collaboration. Collaboration meta-anaylsis of randomised trials of antiplatelet therapy for prevention of death, myocadial infraction and stroke in high risk patients. BMJ, 2002, 324:71-86.
5Hennekens CH. Update on aspirin in the treatment and prevention of cardiovascular disease. Am J Manag Care, 2002, 8(22 Suppl): S691-700.
6Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192 036 patients enrolled in 31 randomized controlled trials. Am J Cardiol, 2005, 95(10): 1218-1222.
7CAPRIE Setering Committee A randomised, blnided, trail of colpidogrel versus aspirin in paitents at risk of ischaemic events (CAPRIE). Lancet, 1996, 348:1329-1339.
8Marshall T. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study. Eur J Cardiovasc Prey Rehabil, 2006, 13(4): 523-528.
二级参考文献12
1Lauer MS. Aspirin for primary prevention of coronary events. N Engl J Med, 2002,346:1468-1474.
2Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest, 2004,126:234S-264S.
3Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction,and stroke in high-risk patients. BMJ, 2002,324:71-86.
4Physicians'Health Study Research Group (PHS). N Engl J Med, 1989,321:129-135.
5Randomised trial of prophylatic daily aspirin in British male doctors (BMD). Br Med J,1988,296:313.
7Collaborative Group of the Primary Prevention Project (PPP). Lancet,2001, 357: 89-95.
8US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med ,2002,136:157-160.
9Pearson TA, Blair SN, Daniels SR. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation , 2002,106:388-391.
10Colwell JA; American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care , 2004,27 Suppl 1:S72-73.